modelR06AX25
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Mizolastine | |
| ATC code: | R06AX25 | route: | oral |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 40 | L |
| clearance: | 10.3 | L/h |
| other parameters in model implementation | ||
Mizolastine is a second-generation non-sedating antihistamine used to treat allergic rhinitis and urticaria. It works by selectively antagonizing peripheral H1 histamine receptors, reducing allergic symptoms. The drug is approved and used in several countries, though not available in the United States.
Pharmacokinetics
Pharmacokinetics in healthy adult volunteers after oral single-dose administration.
References
Lebrun-Vignes, B, et al., & Chosidow, O (2001). Clinical pharmacokinetics of mizolastine. Clinical pharmacokinetics 40(7) 501–507. DOI:10.2165/00003088-200140070-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11510627
Li, P, et al., & Zhang, GL (2018). Effects of UGT1A1, CYP3A5 and ABCB1 Genetic Variants on Pharmacokinetics of Antihistamine Drug Mizolastine in Chinese Healthy Volunteers. Basic & clinical pharmacology & toxicology 123(4) 464–473. DOI:10.1111/bcpt.13028 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29702735
Simons, FE (2002). Comparative pharmacology of H1 antihistamines: clinical relevance. The American journal of medicine 113 Suppl 9A 38S–46S. DOI:10.1016/s0002-9343(02)01436-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12517581
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)